BMY · Bristol-Myers Squibb Co
United States · RS rating 76 · As of 2026-11-03
| Price | 61.71 USD |
|---|---|
| 1-day change | -2.1% |
| RS rating (overall / 1M / 3M / 12M) | 76 / 71 / 62 / 80 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 41 / 38 / 45 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | -50.9% |
| Sales growth Q/Q | +2.3% |
| Distance from 52-week high | +9.4% |
| Market cap (USD) | $120.5B |